Virulence determinants of West Nile virus: How can these be used for vaccine design?

Jaclyn A. Kaiser; Tian Wang; Alan D.T. Barrett

doi:10.2217/fvl-2016-0141

Virulence determinants of West Nile virus: How can these be used for vaccine design?

Jaclyn A. Kaiser, Tian Wang, Alan D.T. Barrett

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

West Nile virus (WNV), a neurotropic mosquito-borne flavivirus, has become endemic in the USA and parts of Europe since 1999. There is no licensed WNV vaccine for humans. Considering the robust immunity from immunization with live, attenuated vaccines, a live WNV vaccine is an ideal platform for disease control. Animal and mosquito studies have identified a number of candidate attenuating mutations, including the structural proteins premembrane/membrane and envelope, and the nonstructural proteins NS1, NS2A, NS3, NS4A, NS4B and NS5, and the 3′ UTR. Many of the mutations that have been examined attenuate WNV using different mechanisms, thus providing a greater understanding of WNV virulence while also identifying specific mutations as candidates to include in a WNV live vaccine.

Original language	English (US)
Pages (from-to)	283-295
Number of pages	13
Journal	Future Virology
Volume	12
Issue number	5
DOIs	https://doi.org/10.2217/fvl-2016-0141
State	Published - May 2017

Keywords

West Nile virus
attenuation
flavivirus
live attenuated vaccine
virulence

ASJC Scopus subject areas

Virology

Access to Document

10.2217/fvl-2016-0141

Cite this

@article{2540f675cf564bfbbe1f12089e40f5ee,

title = "Virulence determinants of West Nile virus: How can these be used for vaccine design?",

abstract = "West Nile virus (WNV), a neurotropic mosquito-borne flavivirus, has become endemic in the USA and parts of Europe since 1999. There is no licensed WNV vaccine for humans. Considering the robust immunity from immunization with live, attenuated vaccines, a live WNV vaccine is an ideal platform for disease control. Animal and mosquito studies have identified a number of candidate attenuating mutations, including the structural proteins premembrane/membrane and envelope, and the nonstructural proteins NS1, NS2A, NS3, NS4A, NS4B and NS5, and the 3′ UTR. Many of the mutations that have been examined attenuate WNV using different mechanisms, thus providing a greater understanding of WNV virulence while also identifying specific mutations as candidates to include in a WNV live vaccine.",

keywords = "West Nile virus, attenuation, flavivirus, live attenuated vaccine, virulence",

author = "Kaiser, {Jaclyn A.} and Tian Wang and Barrett, {Alan D.T.}",

note = "Publisher Copyright: {\textcopyright} 2017 Future Medicine Ltd.",

year = "2017",

month = may,

doi = "10.2217/fvl-2016-0141",

language = "English (US)",

volume = "12",

pages = "283--295",

journal = "Future Virology",

issn = "1746-0794",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - Virulence determinants of West Nile virus

T2 - How can these be used for vaccine design?

AU - Kaiser, Jaclyn A.

AU - Wang, Tian

AU - Barrett, Alan D.T.

PY - 2017/5

Y1 - 2017/5

N2 - West Nile virus (WNV), a neurotropic mosquito-borne flavivirus, has become endemic in the USA and parts of Europe since 1999. There is no licensed WNV vaccine for humans. Considering the robust immunity from immunization with live, attenuated vaccines, a live WNV vaccine is an ideal platform for disease control. Animal and mosquito studies have identified a number of candidate attenuating mutations, including the structural proteins premembrane/membrane and envelope, and the nonstructural proteins NS1, NS2A, NS3, NS4A, NS4B and NS5, and the 3′ UTR. Many of the mutations that have been examined attenuate WNV using different mechanisms, thus providing a greater understanding of WNV virulence while also identifying specific mutations as candidates to include in a WNV live vaccine.

AB - West Nile virus (WNV), a neurotropic mosquito-borne flavivirus, has become endemic in the USA and parts of Europe since 1999. There is no licensed WNV vaccine for humans. Considering the robust immunity from immunization with live, attenuated vaccines, a live WNV vaccine is an ideal platform for disease control. Animal and mosquito studies have identified a number of candidate attenuating mutations, including the structural proteins premembrane/membrane and envelope, and the nonstructural proteins NS1, NS2A, NS3, NS4A, NS4B and NS5, and the 3′ UTR. Many of the mutations that have been examined attenuate WNV using different mechanisms, thus providing a greater understanding of WNV virulence while also identifying specific mutations as candidates to include in a WNV live vaccine.

KW - West Nile virus

KW - attenuation

KW - flavivirus

KW - live attenuated vaccine

KW - virulence

UR - http://www.scopus.com/inward/record.url?scp=85019604822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019604822&partnerID=8YFLogxK

U2 - 10.2217/fvl-2016-0141

DO - 10.2217/fvl-2016-0141

M3 - Review article

C2 - 28919920

AN - SCOPUS:85019604822

SN - 1746-0794

VL - 12

SP - 283

EP - 295

JO - Future Virology

JF - Future Virology

IS - 5

ER -

Virulence determinants of West Nile virus: How can these be used for vaccine design?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this